Has Dawn Ayers, MD received payments from drug or device companies?

Yes. Drug and device makers reported $46,739 in general payments to Dawn Ayers, MD across 800 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dawn Ayers, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dawn Ayers, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dawn Ayers, MD

Endocrinology, Diabetes & Metabolism · Zionsville, INNPI 1306823513

Payments from drug & device makers

$46,739in general payments, 2019–2025

Across 800 payments — averaging $58.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$19K
Johnson & Johnson$14K
Sanofi-aventis U.S. LLC$3K
AstraZeneca$1K
Novo Nordisk$1K
Lilly USA, LLC$1K
plus $7K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	69	$18,753
Johnson & Johnson	29	$14,468
Sanofi-aventis U.S. LLC	43	$2,831
AstraZeneca(2 entities)	69	$1,401
Novo Nordisk	106	$1,353
Lilly USA, LLC	81	$1,130
Amgen(2 entities)	69	$1,067
Boehringer Ingelheim	34	$642
Bayer	31	$497
Abbott	35	$484
Xeris Pharmaceuticals, Inc.	27	$457
Novartis	23	$422
Corcept Therapeutics	16	$319
Mannkind Corporation	21	$288
Medtronic(2 entities)	9	$264
Amneal Pharmaceuticals LLC	12	$218
Tandem Diabetes Care, Inc.	9	$176
Currax Pharmaceuticals LLC	12	$175
Insulet Corporation	8	$128
Merck	8	$121
Antares Pharma, Inc.	6	$104
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$101
Esperion Therapeutics, Inc.	6	$100
Dexcom, Inc.	5	$99
IBSA Pharma Inc.	6	$96
Recordati_rare_diseases_inc.	5	$94
GRT US Holding, Inc.	5	$89
Astellas Pharma US Inc	4	$78
Sequel Med Tech, LLC	4	$71
Amryt Pharma Holdings Ltd	3	$68
Vivus LLC	4	$55
BETA Bionics, Inc.	3	$52
Cequr Corporation	2	$48
Ultragenyx Pharmaceutical Inc.	3	$47
Nevro Corp.	2	$41
Inspire Medical Systems, Inc.	1	$40
Nalpropion Pharmaceuticals LLC	2	$39
Neurocrine Biosciences, Inc.	2	$32
Ascensia Diabetes Care US Inc.	1	$27
Soleno Therapeutics, Inc.	1	$23
Pfizer	1	$19
Grifols USA, LLC	1	$18
Radius Health, Inc.	1	$17
Amarin Pharma, Inc.	1	$17
GSK	1	$17
Companion Medical, Inc.	2	$17
Halozyme Inc	1	$16
Ascendis Pharma Endocrinology Inc	1	$16
Zealand Pharma US, Inc.	1	$15
EUSA Pharma (US) LLC	1	$15
Lifescan, Inc.	1	$14
Otsuka America Pharmaceutical, Inc.	1	$14
Acella Pharmaceuticals, LLC	1	$13
Jazz Pharmaceuticals Inc.	1	$12
Valeritas, Inc.	1	$12
Shire North American Group Inc	1	$12

How this compares

$46,739 in reported general payments places this provider in the 80th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana →

Medicare billing

Part B allowed, 2024

$117,570

Medicare patients

270

Services billed

3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Zionsville

Shahab ZaidiZionsville$3K
Carmella Evans-MolinaIndianapolis$6.3M
Isaiah PittmanTerre Haute$1.5M
Ernest AsamoahIndianapolis$959K
Sana MeahMunster$829K
James MaloneIndianapolis$822K
Erica KretchmanRichmond$636K
Emily VeenemanSeymour$583K
Cary MariashIndianapolis$435K
Marian KirkmanIndianapolis$371K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →